These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

768 related articles for article (PubMed ID: 24030418)

  • 1. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays.
    Navarrete EG; Liang P; Lan F; Sanchez-Freire V; Simmons C; Gong T; Sharma A; Burridge PW; Patlolla B; Lee AS; Wu H; Beygui RE; Wu SM; Robbins RC; Bers DM; Wu JC
    Circulation; 2013 Sep; 128(11 Suppl 1):S3-13. PubMed ID: 24030418
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Electrophysiological characteristics and pharmacological sensitivity of two lines of human induced pluripotent stem cell derived cardiomyocytes coming from two different suppliers.
    Goineau S; Castagné V
    J Pharmacol Toxicol Methods; 2018; 90():58-66. PubMed ID: 29274391
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of Drug Proarrhythmic Potential in Electrically Paced Human Induced Pluripotent Stem Cell-Derived Ventricular Cardiomyocytes Using Multielectrode Array.
    Bai S; Pei J; Chen K; Zhao Y; Cao H; Tian L; Ma Y; Dong H
    SLAS Discov; 2021 Mar; 26(3):364-372. PubMed ID: 32914673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity.
    Liang P; Lan F; Lee AS; Gong T; Sanchez-Freire V; Wang Y; Diecke S; Sallam K; Knowles JW; Wang PJ; Nguyen PK; Bers DM; Robbins RC; Wu JC
    Circulation; 2013 Apr; 127(16):1677-91. PubMed ID: 23519760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CSAHi study: Detection of drug-induced ion channel/receptor responses, QT prolongation, and arrhythmia using multi-electrode arrays in combination with human induced pluripotent stem cell-derived cardiomyocytes.
    Kitaguchi T; Moriyama Y; Taniguchi T; Maeda S; Ando H; Uda T; Otabe K; Oguchi M; Shimizu S; Saito H; Toratani A; Asayama M; Yamamoto W; Matsumoto E; Saji D; Ohnaka H; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 85():73-81. PubMed ID: 28163191
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Electrical Stimulation on hiPSC-CM Responses to Classic Ion Channel Blockers.
    Wei F; Pourrier M; Strauss DG; Stockbridge N; Pang L
    Toxicol Sci; 2020 Apr; 174(2):254-265. PubMed ID: 32040191
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive in vitro cardiac safety assessment using human stem cell technology: Overview of CSAHi HEART initiative.
    Takasuna K; Asakura K; Araki S; Ando H; Kazusa K; Kitaguchi T; Kunimatsu T; Suzuki S; Miyamoto N
    J Pharmacol Toxicol Methods; 2017; 83():42-54. PubMed ID: 27646297
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross - site comparison of excitation-contraction coupling using impedance and field potential recordings in hiPSC cardiomyocytes.
    Bot CT; Juhasz K; Haeusermann F; Polonchuk L; Traebert M; Stoelzle-Feix S
    J Pharmacol Toxicol Methods; 2018; 93():46-58. PubMed ID: 29940218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Action potential-based MEA platform for in vitro screening of drug-induced cardiotoxicity using human iPSCs and rat neonatal myocytes.
    Jans D; Callewaert G; Krylychkina O; Hoffman L; Gullo F; Prodanov D; Braeken D
    J Pharmacol Toxicol Methods; 2017 Sep; 87():48-52. PubMed ID: 28549786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proarrhythmia Risk Assessment in Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes Using the Maestro MEA Platform.
    Qu Y; Vargas HM
    Toxicol Sci; 2015 Sep; 147(1):286-95. PubMed ID: 26117837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Engineered heart tissue models from hiPSC-derived cardiomyocytes and cardiac ECM for disease modeling and drug testing applications.
    Goldfracht I; Efraim Y; Shinnawi R; Kovalev E; Huber I; Gepstein A; Arbel G; Shaheen N; Tiburcy M; Zimmermann WH; Machluf M; Gepstein L
    Acta Biomater; 2019 Jul; 92():145-159. PubMed ID: 31075518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiomyocyte functional screening: interrogating comparative electrophysiology of high-throughput model cell systems.
    Wells SP; Waddell HM; Sim CB; Lim SY; Bernasochi GB; Pavlovic D; Kirchhof P; Porrello ER; Delbridge LMD; Bell JR
    Am J Physiol Cell Physiol; 2019 Dec; 317(6):C1256-C1267. PubMed ID: 31577512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The assessment of electrophysiological activity in human-induced pluripotent stem cell-derived cardiomyocytes exposed to dimethyl sulfoxide and ethanol by manual patch clamp and multi-electrode array system.
    Hyun SW; Kim BR; Hyun SA; Seo JW
    J Pharmacol Toxicol Methods; 2017 Sep; 87():93-98. PubMed ID: 28377112
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An impedance-based approach using human iPSC-derived cardiomyocytes significantly improves in vitro prediction of in vivo cardiotox liabilities.
    Koci B; Luerman G; Duenbostell A; Kettenhofen R; Bohlen H; Coyle L; Knight B; Ku W; Volberg W; Woska JR; Brown MP
    Toxicol Appl Pharmacol; 2017 Aug; 329():121-127. PubMed ID: 28546047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of nefazodone-induced cardiotoxicity in human induced pluripotent stem cell-derived cardiomyocytes.
    Lee S; Lee HA; Choi SW; Kim SJ; Kim KS
    Toxicol Appl Pharmacol; 2016 Apr; 296():42-53. PubMed ID: 26821276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cross-Site Reliability of Human Induced Pluripotent stem cell-derived Cardiomyocyte Based Safety Assays Using Microelectrode Arrays: Results from a Blinded CiPA Pilot Study.
    Millard D; Dang Q; Shi H; Zhang X; Strock C; Kraushaar U; Zeng H; Levesque P; Lu HR; Guillon JM; Wu JC; Li Y; Luerman G; Anson B; Guo L; Clements M; Abassi YA; Ross J; Pierson J; Gintant G
    Toxicol Sci; 2018 Aug; 164(2):550-562. PubMed ID: 29718449
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity Assessment of Drugs Using Human iPS Cell-Derived Cardiomyocytes: Toward Proarrhythmic Risk and Cardio-Oncology.
    Satsuka A; Kanda Y
    Curr Pharm Biotechnol; 2020; 21(9):765-772. PubMed ID: 31264543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety pharmacology studies using EFP and impedance.
    Obergrussberger A; Juhasz K; Thomas U; Stölzle-Feix S; Becker N; Dörr L; Beckler M; Bot C; George M; Fertig N
    J Pharmacol Toxicol Methods; 2016; 81():223-32. PubMed ID: 27084108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes.
    Zhao Q; Wang X; Wang S; Song Z; Wang J; Ma J
    Stem Cell Res Ther; 2017 Mar; 8(1):54. PubMed ID: 28279214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. hiPSC-CM Monolayer Maturation State Determines Drug Responsiveness in High Throughput Pro-Arrhythmia Screen.
    da Rocha AM; Campbell K; Mironov S; Jiang J; Mundada L; Guerrero-Serna G; Jalife J; Herron TJ
    Sci Rep; 2017 Oct; 7(1):13834. PubMed ID: 29061979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.